A

    Anbio Biotechnology Class A Ordinary Shares (NNNN)

    Official site

    HEALTHCARE • MEDICAL INSTRUMENTS & SUPPLIES • NASDAQ

    $7.30
    -0.37 (-4.82%)

    Market Cap: $320.41M

    Last updated: Sep 01, 2026 at 5:00 PM ET

    Earnings

    PeriodReportedEst.SurpriseB/MYoY
    Jun 26
    Reported Jul 7
    		$N/AN/AN/ABeat-
    Sep 25
    Reported Dec 30
    		$0.09$0.00N/ABeat-
    Mar 25
    Reported Apr 28
    		$-0.03$0.00N/AMiss-
    Sep 24
    Reported Dec 31
    		$0.09$0.00N/ABeat-

    Key Metrics

    Valuation
    P/E Ratio121.67EV/EBITDA57.14x
    Price/FCF142.27xFCF Yield0.70%
    Profitability
    Profit Margin74.10%Operating Margin59.10%
    ROE27.10%ROICN/A
    Financial Health
    Debt/EquityN/AInterest CoverageN/A
    Current Ratio344.31xQuick Ratio344.31x
    Trading Statistics
    BetaN/AAvg Volume175.74K
    52-Week High$49.5052-Week Low$6.61

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$7.64
    SMA 20$8.75
    SMA 50$10.40
    SMA 200$22.82
    EMA 10$7.88
    EMA 20$8.57
    EMA 50$11.46
    EMA 200$19.77

    MACD

    Line: -1.04Signal: -1.10Hist: 0.05

    ADX

    ADX: 24.0+DI: 21.8-DI: 15.2

    Aroon & PSAR

    Aroon Up60.0
    Aroon Down76.0
    PSAR$12.13

    Bollinger Bands

    Upper Band$11.28
    Lower Band$6.22
    %B Position5786%(Upper)
    Band Width0.21

    RSI (14-Day)

    Neutral
    34.0

    Momentum Oscillators

    Stoch %K13.5
    Stoch %D15.1
    Williams %R-90.4
    ROC (10d)-14.0%
    Momentum-1.19
    CCI (20d)-84.4
    MFI (14d)59.6

    Volatility Measures

    ATR (14d)$1.42(19.4%)
    StdDev (20d)1.27
    Hist Vol100.2%(High)

    Volume Flow

    VWAP$7.38
    OBV2.3M
    AD Line-1.9M
    CMF (20d)-0.311

    Volume Metrics

    Avg Vol (20d)178.5K
    Vol Ratio1.6x(High)
    VWMA (20d)$8.21

    Pivot Points

    R3$8.51
    R2$8.21
    R1$7.94
    Pivot Point$7.64
    S1$7.38
    S2$7.08
    S3$6.81

    Advanced Oscillators

    TSI-29.32
    Ultimate Osc40.2
    KST-246.55

    Financial Data

    QuarterMar 2026Sep 2025Jun 2025Dec 2024Jun 2024Dec 2023Jun 2023
    Total Revenue$4.74M$2.03M$5.01M$2.53M$6.32M$3.95M$3.31M
    Cost of Revenue$876,722$375,871$384,382$390,512$2.10M$2.26M$1.36M
    Gross Profit$3.86M$1.66M$4.62M$2.14M$4.23M$1.69M$1.94M
    Operating Expenses$1.06M$454,997$945,209$3.87M$337,502$1.11M$406,055
    R&D$81,637$35,000$143,409$353,467$138,025$145,696$0
    SG&A$0$0$0$0$0$0$0
    Operating Income$2.80M$1.20M$3.68M$-1,735,255$3.89M$583,740$1.54M
    Interest Income$0$0$0$0$0$0$0
    Interest Expense$0$0$0$0$1,861$0$0
    Income Before Tax$3.04M$1.30M$4.15M$-1,324,772$3.89M$792,932$1.64M
    Income Tax Expense$0$0$0$0$0$0$0
    Net Income$3.04M$1.30M$4.15M$-1,324,772$3.89M$792,932$1.64M
    EBITDA$2.80MN/A$3.68M$-1,324,776$3.89M$796,474N/A
    EBITN/AN/AN/A$-1,735,255$3.89MN/A$1.54M
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about NNNN

    News

    Price to earnings forward of Anbio Biotechnology Class A – DUS:N3B

    This page on TradingView provides a financial overview of Anbio Biotechnology Class A (DUS:N3B), specifically focusing on its forward price-to-earnings ratio. The article itself is very brief, mainly serving as a placeholder for financial data that would typically be displayed on a TradingView page. It indicates that the market was closed and no trades occurred, with the content being generated by FactSet and American Bankers Association.

    TradingView•7/28/26•
    Neutral

    Price to earnings forward of Anbio Biotechnology Class A – FWB:N3B

    This article provides a brief financial overview for Anbio Biotechnology Class A (FWB:N3B), focusing on its price-to-earnings forward metric. The content indicates that market data is provided by ICE Data Services and reference data by FactSet, with all copyrights reserved up to 2026. The article itself presents very limited actual data, primarily acting as a placeholder within a larger financial platform context.

    TradingView•6/30/26•
    Neutral

    Anbio Biotechnology Soars After Surprise Media Spotlight

    Anbio Biotechnology Class A (NNNN) shares are surging after being featured in a Benzinga article on top healthcare stocks for Q2. This rally is attributed to fresh media exposure, renewed optimism for Anbio's diagnostic portfolio, and a technical rebound, rather than broader sector trends. However, some quantitative models still issue sell signals due to stretched valuation and elevated price-to-book ratio, indicating potential fragility in these sentiment-driven gains.

    TipRanks•6/22/26•
    Bullish

    Frequently Asked Questions About NNNN

    Does NNNN pay dividends?
    Anbio Biotechnology Class A Ordinary Shares (NNNN) does not currently pay a regular dividend.
    What is NNNN's P/E ratio?
    Anbio Biotechnology Class A Ordinary Shares has a price-to-earnings (P/E) ratio of 121.67.
    What is NNNN's market cap?
    Anbio Biotechnology Class A Ordinary Shares (NNNN) has a market capitalization of $320.41M with a current stock price of $7.30.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In